Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
WuXi produces solid oral dosage forms-tablets and capsules-for use inclinical trials in its Shanghai c-GMP manufacturing facility. In itsanalytical testing facility, WuXi develops and validates methods of analyzingAPIs and formulated drug products for properties such as potency, purity andsolubility. The company also offers compound stability tests and testsnecessary for the release of APIs and drug products for clinical trial use.WuXi also delivers services related to regulatory compliance with chemistry,manufacturing and controls, or CMC, requirements, including creation of areadiness testing package for an Investigational New Drug filing anddevelopment of a full CMC package.
Advertisement
"We are very pleased to have passed this EMEA audit," commented Dr. Ge Li,Chairman and Chief Executive Officer of WuXi PharmaTech. "The agency'sinspection outcome confirms that these two facilities meet international GMPstandards.
"We pride ourselves on the quality of our facilities, processes, andpeople," Dr. Li continued. "Research manufacturing and analytical testing areimportant functions in a continuum of integrated drug discovery anddevelopment services that WuXi provides to our global customers. Our missionis to help our global customers to improve the success of discovery andshorten the time of development of new medical products."For more information, please contact: Ronald Aldridge Director of Investor Relations WuXi PharmaTech (Cayman) Inc. Tel: +1-201-585-2048 Email: [email protected] Stephanie Liu Associate Director of Corporate Communications Department Tel: +86-21-5046-4362 Email: [email protected] Web: http://www.wuxiapptec.com
SOURCE WuXi PharmaTech (Cayman) Inc.
